These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 37383395)
21. Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Huixing L; Di F; Daoquan P Clin Ther; 2023 Jan; 45(1):17-30. PubMed ID: 36604209 [TBL] [Abstract][Full Text] [Related]
22. Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes? Bai S; Lin C; Jiao R; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L Eur J Intern Med; 2023 Mar; 109():79-88. PubMed ID: 36628824 [TBL] [Abstract][Full Text] [Related]
24. Cardiovascular safety and benefits of GLP-1 receptor agonists. Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093 [TBL] [Abstract][Full Text] [Related]
25. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423 [TBL] [Abstract][Full Text] [Related]
26. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. Hamid A; Vaduganathan M; Oshunbade AA; Ayyalasomayajula KK; Kalogeropoulos AP; Lien LF; Shafi T; Hall ME; Butler J J Cardiovasc Pharmacol; 2020 Sep; 76(3):313-320. PubMed ID: 32569016 [TBL] [Abstract][Full Text] [Related]
27. [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients]. Zhang Y; Liu S; Fan C; Zeng Y; Li J; Xie C; Xue Y; Guan M Nan Fang Yi Ke Da Xue Xue Bao; 2019 Apr; 39(4):450-455. PubMed ID: 31068289 [TBL] [Abstract][Full Text] [Related]
28. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484 [TBL] [Abstract][Full Text] [Related]
29. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Lovshin JA Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790 [TBL] [Abstract][Full Text] [Related]
30. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Banerjee M; Pal R; Mukhopadhyay S; Nair K J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol. Hussein H; Zaccardi F; Dhalwani NN; Davies MJ; Khunti K; Gray LJ BMJ Open; 2018 Nov; 8(11):e023206. PubMed ID: 30413509 [TBL] [Abstract][Full Text] [Related]
32. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Brunton S Int J Clin Pract; 2014 May; 68(5):557-67. PubMed ID: 24499291 [TBL] [Abstract][Full Text] [Related]
33. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Zhao Z; Tang Y; Hu Y; Zhu H; Chen X; Zhao B Ann Transl Med; 2021 Sep; 9(18):1482. PubMed ID: 34734034 [TBL] [Abstract][Full Text] [Related]
34. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Sloan LA J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152 [TBL] [Abstract][Full Text] [Related]
35. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080 [TBL] [Abstract][Full Text] [Related]
37. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review. Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594 [TBL] [Abstract][Full Text] [Related]
38. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Seufert J; Gallwitz B Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150 [TBL] [Abstract][Full Text] [Related]
39. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774 [TBL] [Abstract][Full Text] [Related]